NCCS Starburst 250px

What Caught Our Eye: ACA Replacement Bill Analysis; Cancer Care Reality in an “Ocean of Hype;” a Highly Effective CML Drug

/in , , , , , /by
What Caught Our Eye (WCOE), March 10, 2017
What Caught Our Eye is our week-in-review blog series, where we recap the cancer policy articles, studies, and stories that caught our attention.

Affordable Care Act

Replacement Bill Introduced In Congress

The American Health Care Act (AHCA) was introduced in the House earlier this week. A great deal has been written analyzing this legislation, and so we only highlight a few articles here looking at different aspects.

A thorough summary of the legislation:

A breakdown of the premium cost changes:

CBPP Analysis of the Bill

The Center on Budget and Policy Priorities has a lot of excellent analysis on the AHCA. This article highlights the fact that “in 11 states, tax credits would be cut more than in half” to help people pay their premiums. It also states: “Consumers’ costs would probably increase even more than tax credits would fall, since the House plan would likely cause individual market premiums to rise.”

ACA Support Continues to Climb

While repeal and replacement of the ACA is being debated, the law is seeing some of its highest support on record.

Cancer Policy

The Reality of Cancer Care

STAT News has an honest and sobering article about the need to “do better in communicating the reality of cancer care to patients.”

Cancer drugs are all too often hailed as miracles, breakthroughs, game-changers, or even cures, even when they are no such thing. We recently reported in JAMA Oncology that these words were used 50 percent of the time to describe drugs not approved by the FDA, and 14 percent of the time to describe drugs that had only worked in mice.

Palliative Care

Palliative care is still misunderstood, often incorrectly equated to end-of-life care or hospice. Palliative and end-of-life care must be seen as two different types of care, each offering distinct benefits for cancer patients when appropriate. “How and when people are referred to palliative care should be prioritised according to cancer patients, a new study in the Oncology Nursing Forum has found.”

Coping With Cancer

Some Patients Discontinuing Highly-Effective CML Drug

A drug used to treat Chronic Myelogenous Leukemia (CML) has been so effective that some doctors now discuss discontinuing treatment with certain patients.

Imagine you had a life-threatening cancer that a wonder drug had kept in remission for years. Would you risk quitting? Thousands of people with a blood cancer called chronic myelogenous leukemia, or CML, now have that choice.

More From “What Caught Our Eye” »

Follow us on Twitter: @canceradvocacy

You might also like
prevent cancer Guest Post: The Progress of Prevention—The Culmination of 20 Years of Advocacy
NCCS News Cancer Policy Matters Patient and Consumer Groups Urge Federal Court to Issue Preliminary Injunction Against Short-Term Insurance Rule
NCCS Starburst 250px What Caught Our Eye: How the Senate Tax Bill Affects Health Care, Surgical Relief for Lymphedema, and An Investigation Into Exorbitant Costs of Care
Carole McCue1 Guest Post: Study Reports Nurse Navigators Make a Difference
NCCS Starburst 250px What Caught Our Eye: Advocates Raise Their Voices Over ACA Repeal; CDC Finds Disparity in Rural Cancer Deaths; Genetic Privacy; and More
NCCS Starburst Thumbnail WCOE: Warlike Metaphors, a Report out of the San Antonio Breast Cancer Symposium, Discussing Costs, and Other News
FacebookProfile3 What Healthcare Reform Means to Cancer Survivors
PETERBACHthumb Guest Post by Peter Bach: Lung Cancer Awareness Month Brings a Long-Awaited Nod to Lung Cancer Screening

Take Action

Stovall Award

The Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care is a unique opportunity for patients and survivors to recognize pioneers who are transforming the cancer care system.

Join CPAT

The NCCS Cancer Policy & Advocacy Team (CPAT) is a program for survivors and caregivers to learn about pressing policy issues that affect quality cancer care in order to be engaged as advocates in public policy around the needs of cancer survivors.

Share Your Story

NCCS represents the millions of Americans who share a common experience – the survivorship experience – living with, through and beyond a cancer diagnosis.

STAY CONNECTED

Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action

National Coalition for Cancer Survivorship
8455 Colesville Road  |  Suite 930  |  Silver Spring, MD 20910
877-NCCS-YES  |  info@canceradvocacy.org
Privacy Policy  |  Terms and Conditions

Copyright © 1995-2020 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.

ACA Update | March 10, 2017: GOP Repeal Plan, the AHCA, Moves Forward in the... ProtectOurCare 1024px ProtectOurCare 1024px NCCS Statement on CBO Score of the American Health Care Act (AHCA)